---

MPLN attending AMP 2016 showcasing IgVH SHM by NGS

Meet MPLN's Dr. Bevan Tandon at Poster H50 for discussions on IgVH Somatic Hypermutation (SHM) by NGS.

Using a next generation sequencing-based approach to IgVH SHM detection, the MPLN methodology utilizes patient DNA as a sample starting…
Read more

---

Letter to JAMA editor discussing colon cancer screening

Dr Nicholas T. Potter Executive Vice President of Clinical Affairs at Molecular Pathology Laboratory Network Inc (MPLN), in a recent letter to the editor of Journal of the American Medical Association (JAMA) Oct 25 2016, clarified the performance…
Read more

---

MPLN expands their oncology offering in CLL/SLL with IgVH Somatic Hypermutation by NGS

CLL/SLL is the most common leukemia diagnosed among adults in Western countries and is associated with heterogeneous clinical outcomes.  IgVH somatic hypermutation (SHM) status is a primary component of the CLL International Prognostic Index…
Read more

---

New Legislation for Blood Based Testing for Colorectal Cancer Screening

The 'Donald Payne Sr. Colorectal Cancer Detection Act of 2016" was introduced by Congressman Donald M. Payne, Jr. (D-NJ) and co-sponsored by Congressman Charles Dent (R-PA) and Congressman John Delaney (D-MD) in Washington D.C on Sept 29th.…
Read more

---

MPLN expands their oncology testing repertoire with PD-L1 and PD-1 immunohistochemistry assays

Molecular Pathology Laboratory Network Inc. launches Ventana PD-L1 and PD-1 assays, expanding their oncology immunohistochemistry menu of tests for NSCLC and other tumor types. MPLN’s repertoire of integrated testing now includes the addition…
Read more

---

← prev 1 2 3 4 5 6 7 8 next →